CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病

Abstract

Recommended Article

Long-term effects of intensive glucose lowering on cardiovascular outcomes Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies Simple Electrocardiographic Measures Improve Sudden Arrhythmic Death Prediction in Coronary Disease Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Original Research2008 Jun;57(6):1702-6.

JOURNAL:Diabetes. Article Link

Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes

Costacou T, Ferrell RE, Orchard TJ. Keywords: T1DM; haptoglobin genotype; haptoglobin 2/2 genotype;

FULL TEXT PDF